Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended
Jul. 31, 2024
Jul. 31, 2023
Income Statement [Abstract]    
Revenue $ 0 $ 0
Operating expenses:    
Research and development costs 96,016 104,483
Compensation expense 389,484 239,998
Director fees 138,000 50,215
Legal and professional 510,556 325,228
General and administrative 134,831 1,355,402
Total operating expenses 1,268,887 2,075,326
Loss from operations (1,268,887) (2,075,326)
Other income (expenses):    
Interest income 547,432 875,878
Change in fair value of warrant liability 2,084,000 (1,452,000)
Change in fair value of derivative liability 1,204,000 (530,000)
Change in fair value of convertible note receivable 245,000 0
Change in fair value of warrant asset – Femasys (1,510,000) 0
Change in fair value of investment – TNF 724,266 0
Gain on related party investment - TNF 21,395,734 0
Other expenses (190) (1,849)
Total other income (expenses), net 24,690,242 (1,107,971)
Net income (loss) 23,421,355 (3,183,297)
Preferred stock dividends (685,801) (319,849)
Preferred stock accretion (2,148,047) (3,272,033)
Net income (loss) attributable to common stockholders $ 20,587,507 $ (6,775,179)